Organon & Co. (OGN) Expected to Release Quarterly Earnings on Monday

Organon & Co. (NYSE:OGN – Get Free Report) is expected to be announcing its Q3 2026 resultson Monday, November 9th. Analysts expect the company to announce earnings of $0.88 per share and revenue of $1.58 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 7:00 AM ET.

Organon & Co. (NYSE:OGN – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.88 by $0.06. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. On average, analysts expect Organon & Co. to post $3.24 EPS for the current fiscal year and $3.43 EPS for the next fiscal year.

Organon & Co. Stock Performance

OGN opened at $13.84 on Friday. The business has a 50 day moving average price of $13.75 and a two-hundred day moving average price of $11.60. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.02 and a quick ratio of 1.44. The company has a market capitalization of $3.63 billion, a price-to-earnings ratio of 18.20, a price-to-earnings-growth ratio of 1.28 and a beta of 1.53. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.88.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, November 9th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.53%.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Five equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $11.40.

Get Our Latest Stock Report on OGN

Organon & Co. Company Profile

(Get Free Report)

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.

Featured Stories

Earnings History for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.